Osaka University Graduate School of Medicine and Faculty of Medicine, Obstetrics & Gynecology.
Hisamatsu Maternity Clinic.
Hum Vaccin Immunother. 2022 Dec 31;18(1):1951098. doi: 10.1080/21645515.2021.1951098. Epub 2021 Nov 22.
Human papillomavirus (HPV) vaccine has been used to prevent chronic HPV infection, which accounts for cervical cancer. Japanese Ministry of Health, Labor and Welfare (MHLW) conducted an HPV vaccination campaign in 2010 and the Obstetrical Gynecological Society of Osaka initiated a multicenter, prospective cohort study in Osaka, Japan - OCEAN (Osaka Clinical resEArch of HPV vacciNe) study - to investigate the oncogenic HPV prevalence and the long-term protection rate of HPV vaccine. A total of 2814 participants were enrolled on their visit for HPV vaccination between 12 and 18 years old. Among them, 102 participants received HPV/Pap co-test as primary cancer screening at the age of 20-21. We compared the prevalence in two groups (the vaccinated and the unvaccinated group). HPV infection ratio was significantly lower in the vaccinated group compared to the unvaccinated (12.9% vs. 19.7%; = .04). In particular, HPV 16 and 18 were not detected in the vaccinated group, while 4.9% of participants in the unvaccinated group were infected ( = .001), suggesting that vaccination provided effective protection against high-risk types of HPV. The cross-protection effect of HPV vaccines was also observed against HPV 31, 45, and 52. Although HPV vaccines were not contributed to the reduction of cervical intraepithelial neoplasia 1 (CIN) ( = .28), CIN2 or worse was not observed in vaccinated group. Our research showed that at the age of 20-21, HPV vaccine inhibited the infection of high-risk HPV and had impacted on the development to CIN2 or worse in Japan.
人乳头瘤病毒（HPV）疫苗已被用于预防慢性 HPV 感染，而慢性 HPV 感染是导致宫颈癌的主要原因。日本厚生劳动省（MHLW）于 2010 年开展了 HPV 疫苗接种活动，大阪妇产科协会在日本大阪启动了一项多中心、前瞻性队列研究——OCEAN（大阪 HPV 疫苗临床研究）研究，以调查致癌 HPV 的流行率以及 HPV 疫苗的长期保护率。共有 2814 名 12-18 岁的参与者在接受 HPV 疫苗接种时入组。其中，102 名参与者在 20-21 岁时接受了 HPV/Pap 联合检测作为原发性癌症筛查。我们比较了两组（接种组和未接种组）的流行率。接种组 HPV 感染率显著低于未接种组（12.9%比 19.7%； = .04）。特别是，接种组未检测到 HPV16 和 HPV18，而未接种组有 4.9%的参与者感染（ = .001），表明疫苗接种对高危型 HPV 提供了有效保护。HPV 疫苗也观察到对 HPV31、45 和 52 的交叉保护作用。尽管 HPV 疫苗对宫颈上皮内瘤变 1 级（CIN1）的减少没有贡献（ = .28），但接种组未观察到 CIN2 或更高级别病变。我们的研究表明，在 20-21 岁时，HPV 疫苗抑制了高危型 HPV 的感染，并对日本 CIN2 或更高级别病变的发展产生了影响。
